TNFRSF17 and Miyoshi myopathy: High levels of soluble BCMA are present in RRMM, and a clinical trial is testing the combination of anti-BCMA CAR-T therapy with γ-secretase inhibitor to block BCMA cleavage from the MM cell surface (NCT03502577).